- Coenzyme Q10
Coenzyme Q10 Identifiers CAS number PubChem ChemSpider UNII ChEBI ChEMBL ATC code C01 Jmol-3D images Image 1 Properties Molecular formula C59H90O4 Molar mass 863.34 g mol−1 Related compounds Related compounds 1,4-Benzoquinone
(what is: /?)
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Coenzyme Q10, also known as ubiquinone, ubidecarenone, coenzyme Q, and abbreviated at times to CoQ10 /ˌkoʊ ˌkjuː ˈtɛn/, CoQ, Q10, or Q, is a 1,4-benzoquinone, where Q refers to the quinone chemical group, and 10 refers to the number of isoprenyl chemical subunits in its tail.
This oil-soluble, vitamin-like substance is present in most eukaryotic cells, primarily in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP. Ninety-five percent of the human body’s energy is generated this way. Therefore, those organs with the highest energy requirements—such as the heart, liver and kidney —have the highest CoQ10 concentrations. There are three redox states of coenzyme Q10: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol). The capacity of this molecule to exist in a completely oxidized form and a completely reduced form enables it to perform its functions in electron transport chain and as an antioxidant respectively.
Discovery and history
Coenzyme Q10 was first discovered by Professor Fredrick L. Crane and colleagues at the University of Wisconsin–Madison Enzyme Institute in 1957. In 1958, its chemical structure was reported by Dr. Karl Folkers and coworkers at Merck; in 1968, Folkers became a Professor in the Chemistry Department at the University of Texas at Austin. In 1961 Peter Mitchel proposed the electron transport chain (which includes the vital protonmotive role of CoQ10) and he received a Nobel prize for the same in 1978. In 1972, Gian Paolo Littarru and Karl Folkers separately demonstrated a deficiency of CoQ10 in human heart disease. The 1980s witnessed a steep rise in the number of clinical trials due to the availability of large quantities of pure CoQ10 and methods to measure plasma and blood CoQ10 concentrations. The antioxidant role of the molecule as a free radical scavenger was widely studied by Lars Ernster. Numerous scientists around the globe started studies on this molecule since then in relation to various diseases including cardiovascular diseases and cancer.
The oxidized structure of CoQ10 is shown on the top-right. The various kinds of Coenzyme Q can be distinguished by the number of isoprenoid subunits in their side-chains. The most common Coenzyme Q in human mitochondria is CoQ10. Q refers to the quinone head and 10 refers to the number of isoprene repeats in the tail. The image below has three isoprenoid units and would be called Q3.
CoQ10 is found in the membranes of many organelles. Since its primary function in cells is in generating energy, the highest concentration is found on the inner membrane of the mitochondrion. Some other organelles that contain CoQ10 include endoplasmic reticulum, peroxisomes, lysosomes, and vesicles.
CoQ10 and electron transport chain
CoQ10 is fat-soluble and is therefore mobile in cellular membranes; it plays a unique role in the electron transport chain (ETC). In the inner mitochondrial membrane, electrons from NADH and succinate pass through the ETC to the oxygen, which is then reduced to water. The transfer of electrons through ETC results in the pumping of H+ across the membrane creating a proton gradient across the membrane, which is used by ATP synthase (located on the membrane) to generate ATP. CoQ10 functions as an electron carrier from enzyme complex I and enzyme complex II to complex III in this process. This is crucial in the process, since no other molecule can perform this function. Thus, CoQ10 functions in every cell of the body to synthesize energy.
Antioxidant function of CoQ10
The antioxidant nature of CoQ10 derives from its energy carrier function. As an energy carrier, the CoQ10 molecule is continually going through an oxidation-reduction cycle. As it accepts electrons, it becomes reduced. As it gives up electrons, it becomes oxidized. In its reduced form, the CoQ10 molecule holds electrons rather loosely, so this CoQ molecule will quite easily give up one or both electrons and, thus, act as an antioxidant. CoQ10 inhibits lipid peroxidation by preventing the production of lipid peroxyl radicals (LOO). Moreover, CoQH2 reduces the initial perferryl radical and singlet oxygen, with concomitant formation of ubisemiquinone and H2O2. This quenching of the initiating perferryl radicals, which prevent propagation of lipid peroxidation, protects not only lipids, but also proteins from oxidation. In addition, the reduced form of CoQ effectively regenerates vitamin E from the a-tocopheroxyl radical, thereby interfering with the propagation step. Furthermore, during oxidative stress, interaction of H2O2 with metal ions bound to DNA generates hydroxyl radicals and CoQ efficiently prevents the oxidation of bases, in particular, in mitochondrial DNA. In contrast to other antioxidants, this compound inhibits both the initiation and the propagation of lipid and protein oxidation. It also regenerates other antioxidants such as vitamin E. The circulating CoQ10 in LDL prevents oxidation of LDL, therefore, by providing its benefits in cardiovascular diseases.
Starting from acetyl-CoA, a multistep process of mevalonate pathway produces farnesyl-PP (FPP), the precursor for cholesterol, CoQ, dolichol, and isoprenylated proteins. An important enzyme in this pathway is HMG Co-A reductase, which is usually a target for intervention in cardiovascular complications. The long isoprenoid side-chain of CoQ is synthesized by trans-prenyltransferase, which condenses FPP with several molecules of isopentenyl-PP (IPP), all in the trans configuration. The next step involves condensation of this polyisoprenoid side-chain with 4-hydroxybenzoate, catalyzed by polyprenyl-4-hydroxy benzoate transferase. Hydroxybenzoate is synthesized from tyrosine or phenylalanine. In addition to their presence in mitochondria, these initial two reactions also occur in the endoplasmic reticulum and peroxisomes, indicating multiple sites of synthesis in animal cells. Increasing the endogenous biosynthesis of CoQ10 has attained attention in the recent years as a strategy to fight CoQ10 deficiency.
Absorption and metabolism
CoQ10 is a crystalline powder that is insoluble in water. Absorption follows the same process as that of lipids and the uptake mechanism appears to be similar to that of vitamin E, another lipid-soluble nutrient.This process in the human body involves the secretion of pancreatic enzymes and bile into the small intestines that facilitate emulsification and micelle formation that is required for the absorption of lipophilic substances. Food intake (and the presence of lipids) stimulates bodily biliary excretion of bile acids and greatly enhances the absorption of CoQ10. Exogenous CoQ10 is absorbed from the small intestinal tract and is best absorbed if it is taken with a meal. Serum concentration of CoQ10 in fed condition is higher than in fasting conditions.
Data on the metabolism of CoQ10 in animals and humans are limited. A study with 14C-labeled CoQ10 in rats showed most of the radioactivity in the liver 2 hours after oral administration when the peak plasma radioactivity was observed, but it should be noted that CoQ9 is the predominant form of coenzyme Q in rats. It appears that CoQ10 is metabolised in all tissues, while a major route for its elimination is biliary and fecal excretion. After the withdrawal of CoQ10 supplementation, the levels return to normal within a few days, irrespective of the type of formulation used.
CoQ10 deficiency and toxicity
There are two major factors that lead to deficiency of CoQ10 in humans: reduced biosynthesis, and increased utilization by the body. Biosynthesis is the major source of CoQ10. Biosynthesis requires at least 12 genes, and mutations in many of them cause CoQ deficiency. CoQ10 levels can also can be affected by other genetic defects (such as mutations of mitochondrial DNA, ETFDH, APTX and BRAF, genes that are not directly related to the CoQ10 biosynthetic process) while the role of statins is controversial. Some chronic disease conditions (cancer, heart disease, etc.) are also thought to reduce the biosynthesis and increase the demand for CoQ10 in the body, but there is no definite data to support these claims. Toxicity is not usually observed with high doses of CoQ10. A daily dosage up to 3600 mg was found to be tolerated by healthy as well as unhealthy persons. However, some adverse effects, largely gastrointestinal, are reported with very high intakes. The observed safe level (OSL) risk assessment method indicated that the evidence of safety is strong at intakes up to 1200 mg/day, and this level is identified as the OSL.
Clinical assessment techniques
Although CoQ10 can be measured in plasma, these measurements reflect dietary intake rather than tissue status. Currently, most clinical centers measure CoQ10 levels in cultured skin fibroblasts, muscle biopsies, and in blood mononuclear cells. Culture fibroblasts can be used also to evaluate the rate of endogenous CoQ10 biosynthesis, by measuring the uptake of 14C-labelled p-hydroxybenzoate.
Inhibition by statins and beta blockers
Coenzyme Q10 shares a biosynthetic pathway with cholesterol. The synthesis of an intermediary precursor of coenzyme Q10, mevalonate, is inhibited by some beta blockers, blood pressure-lowering medication, and statins, a class of cholesterol-lowering drugs. Statins can reduce serum levels of coenzyme Q10 by up to 40%. Some research suggests the logical option of supplementation with coenzyme Q10 as a routine adjunct to any treatment that may reduce endogenous production of coenzyme Q10, based on a balance of likely benefit against very small risk.. However, there are still no conclusive data that support the role of CoQ10 deficiency in the pathogenesis of statin-related myopathy.
Some reports have been published on the pharmacokinetics of CoQ10. The plasma peak can be observed 2–6 hours after oral administration, mainly depending on the design of the study. In some studies, a second plasma peak was also observed at about 24 hours after administration, probably due to both enterohepatic recycling and redistribution from the liver to circulation. Tomono et al. used deuterium-labelled crystalline CoQ10 to investigate pharmacokinetics in human and determined an elimination half-time of 33 hours.
Improving the bioavailability of CoQ10
The importance of how drugs are formulated for bioavailability is well known. In order to find a principle to boost the bioavailability of CoQ10 after oral administration, several new approaches have been taken and different formulations, and forms have been developed and tested on animals or humans.
Reduction of particle size
An obvious strategy is reduction of the particle size to as low as the micro- and nano-scale. Nanoparticles have been explored as a delivery system for various drugs and an improvement of the oral bioavailability of drugs with poor absorption characteristics has been reported; the pathways of absorption and the efficiency were affected by reduction of particle size. This protocol has so far not proved to be very successful with CoQ10, although reports have differed widely. The use of the aqueous suspension of finely powdered CoQ10 in pure water has also revealed only a minor effect.
Soft-gel capsules with CoQ10 in oil suspension
A successful approach was to use the emulsion system to facilitate absorption from the gastrointestinal tract and to improve bioavailability. Emulsions of soybean oil (lipid microspheres) could be stabilised very effectively by lecithin and were utilised in the preparation of soft gelatine capsules. In one of the first such attempts, Ozawa et al. performed a pharmacokinetic study on beagle dogs in which the emulsion of CoQ10 in soybean oil was investigated; about two times higher plasma CoQ10 level than that of the control tablet preparation was determined during administration of a lipid microsphere. Although an almost negligible improvement of bioavailability was observed by Kommuru et al. with oil-based soft-gel capsules in a later study on dogs, the significantly increased bioavailability of CoQ10 was confirmed for several oil-based formulations in most other studies.
Novel forms of CoQ10 with increased water-solubility
Facilitating drug absorption by increasing its solubility in water is a common pharmaceutical strategy and has also been shown to be successful for Coenzyme Q10. Various approaches have been developed to achieve this goal, with many of them producing significantly better results over oil-based soft-gel capsules in spite of the many attempts to optimize their composition. Examples of such approaches are use of the aqueous dispersion of solid CoQ10 with tyloxapol polymer, formulations based on various solubilising agents, i.e., hydrogenated lecithin, and complexation with cyclodextrins; among the latter, complex with β-cyclodextrin has been found to have highly increased bioavailability. and is also used in pharmaceutical and food industry for CoQ10-fortification. Also some other novel carrier systems like liposomes, nanoparticles, dendrimers etc. can be used to increase the bioavailability of Coenzyme Q10.
According to the Mayo Clinic, "CoQ10 has been used, recommended, or studied for numerous conditions, but remains controversial as a treatment in many areas." Coenzyme Q-10 is approved for use as an orphan product in the treatment of Huntington's disease and mitochondrial cytopathies; other uses are still unproven, including in the treatment of congestive heart failure and athletic performance.
Coenzyme Q10 helps to maintain a healthy cardiovascular system. There is evidence of CoQ10 deficiency in heart failure. Recently, CoQ10 plasma concentrations have been demonstrated as an independent predictor of mortality in chronic heart failure, CoQ10 deficiency being detrimental to the long-term prognosis of chronic heart failure. CoQ10 is available as medicine in several European countries, but is in these countries also available as a food supplement. Oxidation of the circulating LDL is thought to play a key role in the pathogenesis of atherosclerosis, which is the underlying disorder leading to heart attack and ischemic strokes and CHD. Studies in the last decade have demonstrated that the content of Ubiquinol in human LDL affords protection against the oxidative modifications of LDL themselves, thus lowering their atherogenic potency.
Supplementation of coenzyme Q10 has been found to have a beneficial effect on the condition of some sufferers of migraine headaches. So far, three studies have been done, of which two were small, did not have a placebo group, were not randomized, and were open-label, and one was a double-blind, randomized, placebo-controlled trial, which found statistically significant results despite its small sample size of 42 patients. Dosages were 150 to 300 mg/day.
Another recent study shows a survival benefit after cardiac arrest if coenzyme Q10 is administered in addition to commencing active cooling of the body to 90–93 degrees Fahrenheit (32–34 degrees Celsius).
There are several reports concerning the effect of CoQ10 on blood pressure in human studies.
A recent (2007) meta-analysis of the clinical trials of CoQ10 for hypertension reviewed all published trials of coenzyme Q10 for hypertension, and assessed overall efficacy, consistency of therapeutic action, and side-effect incidence. Meta-analysis was performed in 12 clinical trials (362 patients) comprising three randomized controlled trials, one crossover study, and eight open-label studies. The meta-analysis concluded that coenzyme Q10 has the potential in hypertensive patients to lower systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side-effects.
Studies have shown that diseased gum tissue is deficient in CoQ10 compared to healthy gum tissue. Human clinical trials have suggested a link between oral administration of CoQ10 and improved gingival health, immune response in gum tissues, and a reversal of the diseased gum conditions. In addition to oral supplementation, topical application of CoQ10 on gum tissues has been shown to improve periodontitis and gingivitis conditions.
One study demonstrated that low dosages of coenzyme Q10 reduce oxidation and DNA double-strand breaks, and a combination of a diet rich in polyunsaturated fatty acids and coenzyme Q10 supplementation leads to a longer lifespan in rats. Coles and Harris demonstrated an extension in the lifespan of rats when they were given coenzyme Q10 supplementation. But multiple studies have since found no increase in lifespan or decrease in aging in mice and rats supplemented with coenzyme Q10. Another study demonstrated that coenzyme Q10 extends the lifespan of C. elegans (nematode).
Coenzyme Q10 concentrations in foods and dietary intake
Detailed reviews on occurrence of CoQ10 and dietary intake were published recently. Besides endogenous synthesis, CoQ10 is also supplied to the organism by various foods. However, despite the scientific community’s great interest in this compound, a very limited number of studies have been performed to determine the contents of CoQ10 in dietary components. The first reports on this issue were published in 1959, but the sensitivity and selectivity of the analytical methods at that time did not allow reliable analyses, especially for products with low concentrations. Developments in analytical chemistry have since enabled a more reliable determination of CoQ10 concentrations in various foods (Table below).
CoQ10 levels in selected foods Food Coenzyme Q10 concentration [mg/kg] Beef heart 113 liver 39–50 muscle 26–40 Pork heart 11.8–128.2 liver 22.7–54.0 muscle 13.8–45.0 Chicken heart 116.2–132.2 Fish sardine 5–64 mackerel red flesh 43–67 white flesh 11–16 salmon 4–8 tuna 5 Oils soybean 54–280 olive 4–160 grapeseed 64–73 sunflower 4–15 rice bran / coconut Nuts peanuts 27 walnuts 19 sesame seeds 18–23 pistachio nuts 20 hazelnuts 17 almond 5–14 Vegetables parsley 8–26 broccoli 6–9 cauliflower 2–7 spinach up to 10 grape 6–7 Chinese cabbage 2–5 Fruit avocado 10 blackcurrant 3 strawberry 1 orange 1–2 grapefruit 1 apple 1
Meat and fish are the richest source of dietary CoQ10 and levels over 50 mg/kg can be found in beef, pork and chicken heart, and chicken liver. Dairy products are much poorer sources of CoQ10 compared to animal tissues. Vegetable oils are also quite rich in CoQ10. Within vegetables, parsley, and perilla are the richest CoQ10 sources, but significant differences in their CoQ10 levels can be found in the literature. Broccoli, grape, and cauliflower are modest sources of CoQ10. Most fruit and berries represent a poor to very poor source of CoQ10, with the exception of avocado, with a relatively high CoQ10 content.
In the developed world, the estimated daily intake of CoQ10 has been determined at 3–6 mg per day, derived primarily from meat.
Effect of heat and processing
Cooking by frying reduces CoQ10 content by 14–32%.
- Idebenone – synthetic analog with reduced oxidant generating properties
- ^ Ernster, L; Dallner, G (1995). "Biochemical, physiological and medical aspects of ubiquinone function". Biochimica et Biophysica Acta 1271 (1): 195–204. PMID 7599208.
- ^ Dutton, PL; Ohnishi, T; Darrouzet, E; Leonard, MA; Sharp, RE; Cibney, BR; Daldal, F; Moser, CC (2000). "4 Coenzyme Q oxidation reduction reactions in mitochondrial electron transport". In Kagan, VE; Quinn, PJ. Coenzyme Q: Molecular mechanisms in health and disease. Boca Raton: CRC Press. pp. 65–82.
- ^ Okamoto, T; Matsuya, T; Fukunaga, Y; Kishi, T; Yamagami, T (1989). "Human serum ubiquinol-10 levels and relationship to serum lipids". International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition 59 (3): 288–92. PMID 2599795.
- ^ Aberg, F; Appelkvist, EL; Dallner, G; Ernster, L (1992). "Distribution and redox state of ubiquinones in rat and human tissues". Archives of biochemistry and biophysics 295 (2): 230–4. doi:10.1016/0003-9861(92)90511-T. PMID 1586151.
- ^ Shindo, Y; Witt, E; Han, D; Epstein, W; Packer, L (1994). "Enzymic and non-enzymic antioxidants in epidermis and dermis of human skin". The Journal of investigative dermatology 102 (1): 122–4. doi:10.1111/1523-1747.ep12371744. PMID 8288904.
- ^ Crane, F; Hatefi, Y; Lester, R; Widmer, C (1957). "Isolation of a quinone from beef heart mitochondria". Biochimica et Biophysica Acta 25 (1): 220–1. doi:10.1016/0006-3002(57)90457-2. PMID 13445756.
- ^ a b Peter H. Langsjoen, "Introduction of Coezyme Q10"[self-published source?]
- ^ Wolf, Donald E.; Hoffman, Carl H.; Trenner, Nelson R.; Arison, Byron H.; Shunk, Clifford H.; Linn, Bruce O.; McPherson, James F.; Folkers, Karl (1958). Journal of the American Chemical Society 80 (17): 4752. doi:10.1021/ja01550a096.
- ^ a b http://www.mbschachter.com/coenzyme_q10.htm
- ^ Tran UC, Clarke CF (June 2007). "Endogenous Synthesis of Coenzyme Q in Eukaryotes". Mitochondrion 7 (Suppl): S62–71. doi:10.1016/j.mito.2007.03.007. PMC 1974887. PMID 17482885. http://linkinghub.elsevier.com/retrieve/pii/S1567-7249(07)00064-5.
- ^ Bentinger M, Tekle M, Dallner G (May 2010). "Coenzyme Q—biosynthesis and functions". Biochem. Biophys. Res. Commun. 396 (1): 74–9. doi:10.1016/j.bbrc.2010.02.147. PMID 20494114. http://linkinghub.elsevier.com/retrieve/pii/S0006-291X(10)00381-5.
- ^ Carmen Espinós; Vicente Felipo; Francesc Palau (1 August 2009). Inherited Neuromuscular Diseases: Translation from Pathomechanisms to Therapies. Springer. pp. 122–. ISBN 9789048128129. http://books.google.com/books?id=uxQ_pjKNhE8C&pg=PA122. Retrieved 4 January 2011.
- ^ a b Bhagavan, Hemmi N.; Chopra, Raj K. (2006). "Coenzyme Q10: Absorption, tissue uptake, metabolism and pharmacokinetics". Free Radical Research 40 (5): 445–53. doi:10.1080/10715760600617843. PMID 16551570.
- ^ Bogentoft 1991[verification needed]
- ^ Ochiai A, Itagaki S, Kurokawa T, Kobayashi M, Hirano T, Iseki K (August 2007). "Improvement in intestinal coenzyme q10 absorption by food intake". Yakugaku Zasshi 127 (8): 1251–4. doi:10.1248/yakushi.127.1251. PMID 17666877. http://joi.jlc.jst.go.jp/JST.JSTAGE/yakushi/127.1251?from=PubMed&lang=en. [verification needed]
- ^ a b c d Zmitek et al. (2008) Agro Food Ind. Hi Tec. 19, 4, 9. – Improving the bioavailability of CoQ10
- ^ Kishi, H.; Kanamori, N.; Nisii, S.; Hiraoka, E.; Okamoto, T.; Kishi, T. (1964). "Metabolism and Exogenous Coenzyme Q10 in vivo and Bioavailability of Coenzyme Q10 Preparations in Japan". Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam: Elsevier. pp. 131–42.
- ^ a b c Ozawa, Y; Mizushima, Y; Koyama, I; Akimoto, M; Yamagata, Y; Hayashi, H; Murayama, H (1986). "Intestinal absorption enhancement of coenzyme Q10 with a lipid microsphere". Arzneimittel-Forschung 36 (4): 689–90. PMID 3718593.
- ^ a b Trevisson E, Dimauro S, Navas P, Salviati L (October 2011). "Coenzyme Q deficiency in muscle". Curr. Opin. Neurol. 24 (5): 449–56. doi:10.1097/WCO.0b013e32834ab528. PMID 21844807. http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=1350-7540&volume=24&issue=5&spage=449.
- ^ Hyson HC, Kieburtz K, Shoulson I, et al. (September 2010). "Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects". Mov. Disord. 25 (12): 1924–8. doi:10.1002/mds.22408. PMID 20669312.
- ^ Hathcock JN, Shao A (August 2006). "Risk assessment for coenzyme Q10 (Ubiquinone)". Regul. Toxicol. Pharmacol. 45 (3): 282–8. doi:10.1016/j.yrtph.2006.05.006. PMID 16814438. http://linkinghub.elsevier.com/retrieve/pii/S0273-2300(06)00090-0.
- ^ Montero R, Sánchez-Alcázar JA, Briones P, et al. (June 2008). "Analysis of coenzyme Q10 in muscle and fibroblasts for the diagnosis of CoQ10 deficiency syndromes". Clin. Biochem. 41 (9): 697–700. doi:10.1016/j.clinbiochem.2008.03.007. PMID 18387363. http://linkinghub.elsevier.com/retrieve/pii/S0009-9120(08)00128-8.
- ^ Kishi, T; Watanabe, T; Folkers, K (1977). "Bioenergetics in clinical medicine XV. Inhibition of coenzyme Q10-enzymes by clinically used adrenergic blockers of beta-receptors". Research communications in chemical pathology and pharmacology 17 (1): 157–64. PMID 17892.
- ^ Mortensen, SA; Leth, A; Agner, E; Rohde, M (1997). "Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors". Molecular aspects of medicine 18 (Suppl): S137–44. PMID 9266515.
- ^ Ghirlanda, G; Oradei, A; Manto, A; Lippa, S; Uccioli, L; Caputo, S; Greco, AV; Littarru, GP (1993). "Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study". Journal of clinical pharmacology 33 (3): 226–9. PMID 8463436.
- ^ Sarter, B (2002). "Coenzyme Q10 and cardiovascular disease: a review". The Journal of cardiovascular nursing 16 (4): 9–20. PMID 12597259.
- ^ Thibault, A; Samid, D; Tompkins, AC; Figg, WD; Cooper, MR; Hohl, RJ; Trepel, J; Liang, B et al. (1996). "Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer". Clinical cancer research 2 (3): 483–91. PMID 9816194.
- ^ Tomono, Y; Hasegawa, J; Seki, T; Motegi, K; Morishita, N (1986). "Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man". International journal of clinical pharmacology, therapy, and toxicology 24 (10): 536–41. PMID 3781673.
- ^ Mathiowitz, Edith; Jacob, Jules S.; Jong, Yong S.; Carino, Gerardo P.; Chickering, Donald E.; Chaturvedi, Pravin; Santos, Camilla A.; Vijayaraghavan, Kavita et al. (1997). "Biologically erodible microspheres as potential oral drug delivery systems". Nature 386 (6623): 410–4. doi:10.1038/386410a0. PMID 9121559.
- ^ Hsu CH, Cui Z, Mumper RJ, Jay M (2003). "Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors". AAPS PharmSciTech 4 (3): E32. doi:10.1208/pt040332. PMC 2750625. PMID 14621964. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2750625. [verification needed]
- ^ Joshi SS, Sawant SV, Shedge A, Halpner AD (January 2003). "Comparative bioavailability of two novel coenzyme Q10 preparations in humans". Int J Clin Pharmacol Ther 41 (1): 42–8. PMID 12564745. [verification needed]
- ^ Kommuru, TR; Ashraf, M; Khan, MA; Reddy, IK (1999). "Stability and bioequivalence studies of two marketed formulations of coenzyme Q10 in beagle dogs". Chemical & pharmaceutical bulletin 47 (7): 1024–8. PMID 10434405.
- ^ Bhagavan HN, Chopra RK (June 2007). "Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations". Mitochondrion 7 (Suppl): S78–88. doi:10.1016/j.mito.2007.03.003. PMID 17482886. http://linkinghub.elsevier.com/retrieve/pii/S1567-7249(07)00061-X. [verification needed]
- ^ K. Westesen and B. Siekmann. Particles with modified physicochemical properties, their preparation and uses. US6197349. 2001.
- ^ H. Ohashi, T. Takami, N. Koyama, Y. Kogure and K. Ida. Aqueous solution containing ubidecarenone. US4483873. 1984
- ^ Žmitek, Janko; Šmidovnik, Andrej; Fir, Maja; Prošek, Mirko; Žmitek, Katja; Walczak, Jaroslaw; Pravst, Igor (2008). "Relative Bioavailability of Two Forms of a Novel Water-Soluble Coenzyme Q10". Annals of Nutrition and Metabolism 52 (4): 281–7. doi:10.1159/000129661. PMID 18645245.
- ^ Kagan, Daniel; Madhavi, Doddabele (2010). "A Study on the Bioavailability of a Novel Sustained-Release Coenzyme Q10-ß-Cyclodextrin Complex". Integrative Medicine 9 (1).
- ^ Mayo Clinic Drugs and Supplements: Coenzyme Q10 . Retrieved 13 November 2008.
- ^ Molyneux SL, Florkowski CM, George PM, et al. (October 2008). "Coenzyme Q10: an independent predictor of mortality in chronic heart failure". J. Am. Coll. Cardiol. 52 (18): 1435–41. doi:10.1016/j.jacc.2008.07.044. PMID 19017509. http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(08)02722-8. [verification needed]
- ^ Witztum, JL (1994). "The oxidation hypothesis of atherosclerosis". Lancet 344 (8925): 793–5. doi:10.1016/S0140-6736(94)92346-9. PMID 7916078.
- ^ Parthasarathy, S; Steinberg, D; Witztum, JL (1992). "The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis". Annual review of medicine 43: 219–25. doi:10.1146/annurev.me.43.020192.001251. PMID 1580586.
- ^ Heller, FR; Descamps, O; Hondekijn, JC (1998). "LDL oxidation: therapeutic perspectives". Atherosclerosis 137 Suppl: S25–31. doi:10.1016/S0021-9150(97)00308-0. PMID 9694538.
- ^ Mohr D, Bowry VW, Stocker R (June 1992). "Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation". Biochim. Biophys. Acta 1126 (3): 247–54. doi:10.1016/0005-2760(92)90237-P. PMID 1637852. http://linkinghub.elsevier.com/retrieve/pii/0005-2760(92)90237-P. [verification needed]
- ^ Alleva R, Tomasetti M, Battino M, Curatola G, Littarru GP, Folkers K (September 1995). "The roles of coenzyme Q10 and vitamin E on the peroxidation of human low density lipoprotein subfractions". Proc. Natl. Acad. Sci. U.S.A. 92 (20): 9388–91. doi:10.1073/pnas.92.20.9388. PMC 40990. PMID 7568138. http://www.pnas.org/cgi/pmidlookup?view=long&pmid=7568138. [verification needed]
- ^ Rozen, TD; Oshinsky, ML; Gebeline, CA; Bradley, KC; Young, WB; Shechter, AL; Silberstein, SD (2002). "Open label trial of coenzyme Q10 as a migraine preventive". Cephalalgia 22 (2): 137–41. doi:10.1046/j.1468-2982.2002.00335.x. PMID 11972582.
- ^ Sándor, PS; Di Clemente, L; Coppola, G; Saenger, U; Fumal, A; Magis, D; Seidel, L; Agosti, RM et al. (2005). "Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial". Neurology 64 (4): 713–5. doi:10.1212/01.WNL.0000151975.03598.ED. PMID 15728298.
- ^ Migraine Action UK
- ^ Sakano, K; Takahashi, M; Kitano, M; Sugimura, T; Wakabayashi, K (2006). "Suppression of azoxymethane-induced colonic premalignant lesion formation by coenzyme Q10 in rats". Asian Pacific journal of cancer prevention : APJCP 7 (4): 599–603. PMID 17250435.
- ^ Coenzyme Q10. NCI
- ^ ClinicalTrials.gov NCT00976131 Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
- ^ ClinicalTrials.gov NCT00096356 Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer
- ^ Damian, M. S.; Ellenberg, D; Gildemeister, R; Lauermann, J; Simonis, G; Sauter, W; Georgi, C (2004). "Coenzyme Q10 Combined With Mild Hypothermia After Cardiac Arrest: A Preliminary Study". Circulation 110 (19): 3011–6. doi:10.1161/01.CIR.0000146894.45533.C2. PMID 15520321.
- ^ Tracy, Melanie Johns (2003). "Ch. 4: Coenzyme Q10 (Ubiquinone, Ubidecarenone)". Dietary supplements: toxicology and clinical pharmacology. Humana Press. pp. 53–85. ISBN 978-1-58829-014-4. http://books.google.com/books?id=JU8xq7IsBYcC&pg=PA53.
- ^ Rosenfeldt, F L; Haas, S J; Krum, H; Hadj, A; Ng, K; Leong, J-Y; Watts, G F (2007). "Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials". Journal of Human Hypertension 21 (4): 297–306. doi:10.1038/sj.jhh.1002138. PMID 17287847.
- ^ Littarru GP, Nakamura R, Ho L, Folkers K, Kuzell WC (October 1971). "Deficiency of Coenzyme Q10 in Gingival Tissue from Patients with Periodontal Disease". Proc. Natl. Acad. Sci. U.S.A. 68 (10): 2332–5. doi:10.1073/pnas.68.10.2332. PMC 389415. PMID 5289867. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=389415.
- ^ Nakamura R, Littarru GP, Folkers K, Wilkinson EG (April 1974). "Study of CoQ10-Enzymes in Gingiva from Patients with Periodontal Disease and Evidence for a Deficiency of Coenzyme Q10". Proc. Natl. Acad. Sci. U.S.A. 71 (4): 1456–60. doi:10.1073/pnas.71.4.1456. PMC 388248. PMID 4151519. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=388248.
- ^ McRee JT, Hanioka T, Shizukuishi S, Folkers K (1993). "Therapy with coenzyme Q10 for patients with periodontal disease". J Dent Health 43 (5): 659–666. doi:10.5834/jdh.43.659.
- ^ Folkers, K; Hanioka, T; Xia, L; McReejr, J; Langsjoen, P (1991). "Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the aids related complex". Biochemical and Biophysical Research Communications 176 (2): 786–91. doi:10.1016/S0006-291X(05)80254-2. PMID 1673841.
- ^ Wilkinson, EG; Arnold, RM; Folkers, K (1976). "Bioenergetics in clinical medicine. VI. adjunctive treatment of periodontal disease with coenzyme Q10". Research communications in chemical pathology and pharmacology 14 (4): 715–9. PMID 785563.
- ^ Hanioka T, Tanaka M, Ojima M, Shizukuishi S, Folkers K (1994). "Effect of topical application of coenzyme Q10 on adult periodontitis". Mol. Aspects Med. 15 (Suppl): S241–8. doi:10.1016/0098-2997(94)90034-5. PMID 7752836.
- ^ Quiles, J; Ochoa, JJ; Huertas, JR; Mataix, J (2004). "Coenzyme Q supplementation protects from age-related DNA double-strand breaks and increases lifespan in rats fed on a PUFA-rich diet". Experimental Gerontology 39 (2): 189–94. doi:10.1016/j.exger.2003.10.002. PMID 15036411.
- ^ Coles L, Harris S (1996). "Coenzyme Q-10 and Lifespan Extension". Advances in Anti-Aging Medicine 1 (1): 205–15.
- ^ Lönnrot, K; Holm, P; Lagerstedt, A; Huhtala, H; Alho, H (1998). "The effects of lifelong ubiquinone Q10 supplementation on the Q9 and Q10 tissue concentrations and life span of male rats and mice". Biochemistry and molecular biology international 44 (4): 727–37. PMID 9584986.
- ^ Lee, C; Pugh, TD; Klopp, RG; Edwards, J; Allison, DB; Weindruch, R; Prolla, TA (2004). "The impact of α-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice". Free Radical Biology and Medicine 36 (8): 1043–57. doi:10.1016/j.freeradbiomed.2004.01.015. PMID 15059645.
- ^ Sohal, Rajindar S.; Kamzalov, Sergey; Sumien, Nathalie; Ferguson, Melissa; Rebrin, Igor; Heinrich, Kevin R.; Forster, Michael J. (2006). "Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice". Free Radical Biology and Medicine 40 (3): 480–7. doi:10.1016/j.freeradbiomed.2005.08.037. PMC 2834650. PMID 16443163. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2834650.
- ^ Sumien, N.; Heinrich, K. R.; Shetty, R. A.; Sohal, R. S.; Forster, M. J. (2009). "Prolonged Intake of Coenzyme Q10 Impairs Cognitive Functions in Mice". Journal of Nutrition 139 (10): 1926–32. doi:10.3945/jn.109.110437. PMC 2744613. PMID 19710165. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2744613.
- ^ Ishii, N; Senoo-Matsuda, N; Miyake, K; Yasuda, K; Ishii, T; Hartman, PS; Furukawa, S (2004). "Coenzyme Q10 can prolong C. elegans lifespan by lowering oxidative stress". Mechanisms of Ageing and Development 125 (1): 41–6. doi:10.1016/j.mad.2003.10.002. PMID 14706236.
- ^ Koryagin, A. S.; Krylova, E. V.; Luk'yanova, L. D. (2002). "Effect of ubiquinone-10 on the blood system in rats exposed to radiation". Bulletin of Experimental Biology and Medicine 133 (6): 562–564. doi:10.1023/A:1020225623808. PMID 12447465.
- ^ "Study Suggests Coenzyme Q10 Slows Functional Decline in Parkinson's Disease". 2002. http://www.ninds.nih.gov/news_and_events/press_releases/pressrelease_parkinsons_coenzymeq10_101402.htm.
- ^ Shults, C. W.; Oakes, D; Kieburtz, K; Beal, MF; Haas, R; Plumb, S; Juncos, JL; Nutt, J et al. (2002). "Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline". Archives of Neurology 59 (10): 1541–50. doi:10.1001/archneur.59.10.1541. PMID 12374491.
- ^ ClinicalTrials.gov NCT00740714 Effects of Coenzyme Q10 (CoQ) in Parkinson Disease (QE3)
- ^ a b c d e Pravst, Igor; Zmitek, Katja; Zmitek, Janko (2010). "Coenzyme Q10 Contents in Foods and Fortification Strategies". Critical Reviews in Food Science and Nutrition 50 (4): 269–80. doi:10.1080/10408390902773037. PMID 20301015.
- ^ Weber, C; Bysted, A; Hłlmer, G (1997). "The coenzyme Q10 content of the average Danish diet". Int J Vitam Nutr Res 67 (2): 123–9. PMID 9129255.
- Coenzyme Q10: An Antioxidant Drug – from the Huntington's Disease Outreach Project for Education at Stanford
- List of USP Verified CoQ10 Ingredients
- Detailed discussion of coenzyme q10 health benefits
- National Cancer Institute page on Coenzyme Q10
- Robert Alan Bonakdar and Erminia Guarneri, American Family Physician page on Coenzyme Q10
- An Introduction to Coenzyme Q10 at University of Washington
- Possible Health Benefits of Coenzyme Q10 at Oregon State University
- Study Suggests Coenzyme Q10 Slows Functional Decline in Parkinson's Disease at National Institute of Neurological Disorders and Stroke
Metabolism: Citric acid cycle enzymes Cycle Anapleroticto acetyl-CoAto succinyl-CoAto oxaloacetate Mitochondrial
electron transport chain/
Enzyme cofactors Active forms Base formsvitamins: see vitamins
cof, enz, met
noco, nuvi, sysi/epon, met
AntioxidantsAcetyl-L-Carnitine (ALCAR) • Alpha-Lipoic Acid (ALA) • Ascorbic Acid (Vitamin C) • Carotenoids (Vitamin A) • Curcumin • Edaravone • Polyphenols • Glutathione • Hydroxytyrosol • L-Carnitine • Ladostigil • Melatonin • N-Acetylcysteine (NAC) • N-Acetylserotonin (NAS) • Oleocanthal • Oleuropein • Rasagiline • Resveratrol • Selegiline • Selenium • Tocopherols (Vitamin E) • Tocotrienols (Vitamin E) • Tyrosol • Ubiquinone (Coenzyme Q) • Uric Acid
Wikimedia Foundation. 2010.
Look at other dictionaries:
Coenzyme Q10 — Structure de la coenzyme Q10 (n = 10) Général Nom IUPAC 2,3 diméthoxy 5 méthyl 6 decaprényl … Wikipédia en Français
coenzyme Q10 — n a ubiquinone C59H90O4 of humans and most other mammals that has a side chain with ten isoprenoid units and possesses antioxidant properties … Medical dictionary
coenzyme Q10 — A substance found in most tissues in the body, and in many foods. It can also be made in the laboratory. It is used by the body to produce energy for cells, and as an antioxidant. It is being studied in the treatment of cancer and in the relief… … English dictionary of cancer terms
Coenzyme Q10 deficiency — Classification and external resources Ubiquinone OMIM 607426 Coenzyme Q10 deficiency is a deficiency of … Wikipedia
Coenzyme Q-10 — Coenzyme Q10 Coenzyme Q10 Général Nom IUPAC 2,3 diméthoxy 5 méthyl 6 decaprénylbenzoquinone Synonymes … Wikipédia en Français
Q10 — or Q 10 may be:* Q10 (role playing game) * The Q10 (New York City bus) * Q10 (temperature coefficient) * Coenzyme Q10, most common form of Coenzyme Q, a vitamin like antioxidant * Q10 (text editor) … Wikipedia
Coenzyme Q - Cytochrome C-réductase — Illustration schématique des réactions du complexe III Le complexe coenzyme Q – cytochrome c réductase, ou complexe bc1, est le 3e complexe de la chaîne oxydative mitochondriale (complexe III), c’est à dire de la chaîne de transport des électrons … Wikipédia en Français
Coenzyme Q - cytochrome c-reductase — Coenzyme Q cytochrome c réductase Illustration schématique des réactions du complexe III Le complexe coenzyme Q – cytochrome c réductase, ou complexe bc1, est le 3e complexe de la chaîne oxydative mitochondriale (complexe III), c’est à dire de la … Wikipédia en Français
Coenzyme Q - cytochrome c-réductase — Illustration schématique des réactions du complexe III Le complexe coenzyme Q – cytochrome c réductase, ou complexe bc1, est le 3e complexe de la chaîne oxydative mitochondriale (complexe III), c’est à dire de la chaîne de transport des électrons … Wikipédia en Français
Coenzyme q - cytochrome c-réductase — Illustration schématique des réactions du complexe III Le complexe coenzyme Q – cytochrome c réductase, ou complexe bc1, est le 3e complexe de la chaîne oxydative mitochondriale (complexe III), c’est à dire de la chaîne de transport des électrons … Wikipédia en Français